Articles tagged with: Revlimid

News»

[ by | Apr 12, 2013 2:16 pm | 2 Comments ]
Update Presented About Cereblon And Resistance To Pomalyst, Revlimid, And Thalidomide In Myeloma Patients (IMW 2013)

During a session at the International Myeloma Workshop (IMW) held in Japan last week, Dr. Keith Stewart from the Mayo Clinic summarized the latest findings from research related to the protein cereblon and its im­pact on certain myeloma treatments.

Dr. Stewart reported that low levels of cereblon are associated with lower re­sponse rates and reduced survival outcomes in multiple myeloma patients treated with the immunomodulatory agents Revlimid (lena­lido­mide), thalidomide (Thalomid), and Pomalyst (pomalidomide).

He explained that, with further investigation, these findings may eventually help physicians customize ther­apy …

Read the full story »

News»

[ by | Apr 9, 2013 10:25 am | One Comment ]
Kyprolis-Revlimid-Dexamethasone Combination Shows Promise In High-Risk Smoldering Myeloma (IMW 2013)

Initial results of an ongoing Phase 2 clinical trial show that Kyprolis in combina­tion with Revlimid and low-dose dexa­meth­a­sone may be effective and safe in high-risk smol­der­ing multiple myeloma patients.

Specifically, the results show that all patients responded to the com­bi­na­tion ther­apy, with 75 per­cent of patients achieving at least a near complete response.

Progression-free or over­all survival results are not yet available, though, to indicate whether the com­bi­na­tion ther­apy delays pro­gres­sion to myeloma or extends over­all survival.

Dr. Ola Landgren from the U.S. National Cancer Institute and National Institutes of Health …

Read the full story »

News»

[ by | Mar 22, 2013 2:52 pm | 4 Comments ]
The Top Myeloma Research Of 2012

Looking back at all that has hap­pened in the world of mul­ti­ple myeloma since Jan­u­ary of 2012, it is hard not to be impressed by the many im­por­tant devel­op­ments that took place.

There is the obvious fact that, during that time, not one, but two new drugs to treat myeloma were approved by the U.S. Food and Drug Adminis­tra­tion (FDA).  Prior to 2012, the FDA had not approved a novel anti-myeloma ther­apy in over six years.

Yet 2012 was meaningful to the myeloma com­munity for reasons beyond the ac­­tiv­ity at the FDA’s …

Read the full story »

News»

[ by | Mar 19, 2013 11:53 am | Comments Off ]
Kyprolis-Revlimid-Dexamethasone Combination Added To NCCN Guidelines As Upfront Therapy For Myeloma

The National Comprehensive Cancer Network (NCCN) recently released an updated version of its guidelines for the diag­nosis and treat­ment of multiple myeloma.

The most notable change to the guidelines is the addi­tion of Kyprolis (carfilz­omib), in com­bi­na­tion with Revlimid (lena­lido­mide) and dexa­metha­sone (Decadron), as an alter­na­tive treat­ment option for newly diagnosed myeloma patients eligible for a stem cell trans­plant.

The guidelines also now list Pomalyst (poma­lido­mide), in com­bi­na­tion with dexa­meth­a­sone, as a preferred salvage treat­ment for myeloma.

NCCN guidelines are followed closely by physicians and by many U.S. health …

Read the full story »

News»

[ by | Mar 8, 2013 5:16 pm | 5 Comments ]
Kyprolis-Revlimid-Dexamethasone Combination Is Effective For Relapsed Myeloma

Results from a Phase 1b clinical trial indicate that Kyprolis in com­bi­na­tion with Revlimid and low-dose dexa­meth­a­sone is effective and safe for re­lapsed multiple myeloma patients.

Moreover, at the higher doses of Kyprolis and Revlimid tested during the trial, a greater share of patients responded to treat­ment than was the case in a trial testing Revlimid, Velcade, and dexa­meth­a­sone in a similar patient population.

In addi­tion, noticeably fewer cases of periph­eral neu­rop­athy – that is, pain, tingling, or loss of sensation in the extremities – were observed in the current study in …

Read the full story »

Opinion»

[ by | Feb 21, 2013 12:44 pm | 29 Comments ]
ME vs. MM: Life After Dex

Perhaps the title of this column more appropriately should be "Life After CRD," since I've now completed 24 cycles of Kyprolis (carfilzomib), Revlimid (lena­lido­mide), and dexa­metha­sone (Decadron), commonly referred to as CRD, as part of a clinical trial for newly diagnosed patients.

However, since dexa­metha­sone seemed to be the predominate source of my side effects, and be­cause I liked the play on words, I went with the title as shown.

So, I've completed the clinical trial, I've reached stringent complete response, and I've won the first …

Read the full story »

News»

[ by | Feb 20, 2013 3:30 pm | Comments Off ]
Velcade-Based Therapy May Improve Outcomes For Myeloma Patients Who Do Not Respond Well To Initial Therapy With Revlimid Or Thalidomide

Results of a small Phase 2 study may lead to improved outcomes for newly diagnosed patients who are unable to achieve a deep response with a Revlimid- or thalidomide-based initial therapy.

The study indicates that follow-on treatment with a Velcade-based regimen can noticeably deepen responses in these patients.

“We were certainly pleased to see that we were able to confirm our hypothesis that offering Velcade-containing, non-cross-resistant combinations to patients whose response had stalled after [Revlimid- or thalidomide-] based therapy can improve the depth of response,” said the study’s lead investigator, Dr. Ruben …

Read the full story »